Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis

PURPOSE: We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate its efficacy and safety in gastric cancer patients with peritoneal carcinomatosis (PC). METHODS: Patients with PC confirmed by la...

Descripción completa

Detalles Bibliográficos
Autores principales: Fushida, S., Kinoshita, J., Kaji, M., Hirono, Y., Goda, F., Yagi, Y., Oyama, K., Sudo, Y., Watanabe, Y., Fujimura, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636429/
https://www.ncbi.nlm.nih.gov/pubmed/23423490
http://dx.doi.org/10.1007/s00280-013-2122-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636429/
https://www.ncbi.nlm.nih.gov/pubmed/23423490
http://dx.doi.org/10.1007/s00280-013-2122-0

Ejemplares similares